The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design

Munyaradzi Dimairo, Philip Pallmann, James Wason, Susan Todd, Thomas Jaki, Steven A Julious, Adrian P Mander, Christopher J Weir, Franz Koenig, Marc K Walton, Jon P Nicholl, Elizabeth Coates, Katie Biggs, Toshimitsu Hamasaki, Michael A Proschan, John A Scott, Yuki Ando, Daniel Hind, Douglas G Altman, ACE Consensus Group, Munyaradzi Dimairo, Philip Pallmann, James Wason, Susan Todd, Thomas Jaki, Steven A Julious, Adrian P Mander, Christopher J Weir, Franz Koenig, Marc K Walton, Jon P Nicholl, Elizabeth Coates, Katie Biggs, Toshimitsu Hamasaki, Michael A Proschan, John A Scott, Yuki Ando, Daniel Hind, Douglas G Altman, ACE Consensus Group

Abstract

Adaptive designs (ADs) allow pre-planned changes to an ongoing trial without compromising the validity of conclusions and it is essential to distinguish pre-planned from unplanned changes that may also occur. The reporting of ADs in randomised trials is inconsistent and needs improving. Incompletely reported AD randomised trials are difficult to reproduce and are hard to interpret and synthesise. This consequently hampers their ability to inform practice as well as future research and contributes to research waste. Better transparency and adequate reporting will enable the potential benefits of ADs to be realised.This extension to the Consolidated Standards Of Reporting Trials (CONSORT) 2010 statement was developed to enhance the reporting of randomised AD clinical trials. We developed an Adaptive designs CONSORT Extension (ACE) guideline through a two-stage Delphi process with input from multidisciplinary key stakeholders in clinical trials research in the public and private sectors from 21 countries, followed by a consensus meeting. Members of the CONSORT Group were involved during the development process.The paper presents the ACE checklists for AD randomised trial reports and abstracts, as well as an explanation with examples to aid the application of the guideline. The ACE checklist comprises seven new items, nine modified items, six unchanged items for which additional explanatory text clarifies further considerations for ADs, and 20 unchanged items not requiring further explanatory text. The ACE abstract checklist has one new item, one modified item, one unchanged item with additional explanatory text for ADs, and 15 unchanged items not requiring further explanatory text.The intention is to enhance transparency and improve reporting of AD randomised trials to improve the interpretability of their results and reproducibility of their methods, results and inference. We also hope indirectly to facilitate the much-needed knowledge transfer of innovative trial designs to maximise their potential benefits.

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Fig 1
Fig 1
Adapted from Steg et al.
Fig 2
Fig 2
Redrawn from Gilson et al. Reused in accordance with the terms of Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/). No changes to the original figure were made.
Fig 3
Fig 3
Redrawn from Pallmann et al. Reused in accordance with the terms of Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/). No changes to the original figure were made.

References

    1. Yordanov Y, Dechartres A, Porcher R, Boutron I, Altman DG, Ravaud P. Avoidable waste of research related to inadequate methods in clinical trials. BMJ 2015;350:h809. 10.1136/bmj.h809
    1. Chen YL, Yang KH. Avoidable waste in the production and reporting of evidence. Lancet 2009;374:786. 10.1016/S0140-6736(09)61591-9
    1. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c869. 10.1136/bmj.c869
    1. Schulz KF, Altman DG, Moher D, CONSORT Group CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med 2010;152:726-32. 10.7326/0003-4819-152-11-201006010-00232
    1. CONSORT Group. Extensions of the CONSORT Statement. .
    1. Ivers NM, Taljaard M, Dixon S, et al. Impact of CONSORT extension for cluster randomised trials on quality of reporting and study methodology: review of random sample of 300 trials, 2000-8. BMJ 2011;343:d5886. 10.1136/bmj.d5886
    1. Moher D, Jones A, Lepage L, CONSORT Group (Consolidated Standards for Reporting of Trials) Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation. JAMA 2001;285:1992-5. 10.1001/jama.285.15.1992
    1. Plint AC, Moher D, Morrison A, et al. Does the CONSORT checklist improve the quality of reports of randomised controlled trials? A systematic review. Med J Aust 2006;185:263-7. 10.5694/j.1326-5377.2006.tb00557.x
    1. Blanco D, Biggane AM, Cobo E, MiRoR network Are CONSORT checklists submitted by authors adequately reflecting what information is actually reported in published papers? Trials 2018;19:80. 10.1186/s13063-018-2475-0
    1. Jin Y, Sanger N, Shams I, et al. Does the medical literature remain inadequately described despite having reporting guidelines for 21 years? - A systematic review of reviews: an update. J Multidiscip Healthc 2018;11:495-510. 10.2147/JMDH.S155103
    1. Janackovic K, Puljak L. Reporting quality of randomized controlled trial abstracts in the seven highest-ranking anesthesiology journals. Trials 2018;19:591. 10.1186/s13063-018-2976-x
    1. Goldacre B, Drysdale H, Dale A, et al. COMPare: a prospective cohort study correcting and monitoring 58 misreported trials in real time. Trials 2019;20:118. 10.1186/s13063-019-3173-2
    1. Dimairo M, Coates E, Pallmann P, et al. Development process of a consensus-driven CONSORT extension for randomised trials using an adaptive design. BMC Med 2018;16:210. 10.1186/s12916-018-1196-2
    1. FDA. Adaptive designs for medical device clinical studies: draft guidance for industry and food and drug administration staff. 2015. .
    1. Chow S-C, Chang M. Adaptive design methods in clinical trials - a review. Orphanet J Rare Dis 2008;3:11. 10.1186/1750-1172-3-11
    1. Dragalin V. Adaptive designs: terminology and classification. Drug Inf J 2006;40:425-35 10.1177/216847900604000408.
    1. Gallo P, Chuang-Stein C, Dragalin V, Gaydos B, Krams M, Pinheiro J, PhRMA Working Group Adaptive designs in clinical drug development--an executive summary of the PhRMA Working Group. J Biopharm Stat 2006;16:275-83, discussion 285-91, 293-8, 311-2. 10.1080/10543400600614742
    1. Kairalla JA, Coffey CS, Thomann MA, Muller KE. Adaptive trial designs: a review of barriers and opportunities. Trials 2012;13:145. 10.1186/1745-6215-13-145
    1. Lewis RJ. The pragmatic clinical trial in a learning health care system. Clin Trials 2016;13:484-92. 10.1177/1740774516655097
    1. Curtin F, Heritier S. The role of adaptive trial designs in drug development. Expert Rev Clin Pharmacol 2017;10:727-36. 10.1080/17512433.2017.1321985
    1. Park JJ, Thorlund K, Mills EJ. Critical concepts in adaptive clinical trials. Clin Epidemiol 2018;10:343-51. 10.2147/CLEP.S156708
    1. Pallmann P, Bedding AW, Choodari-Oskooei B, et al. Adaptive designs in clinical trials: why use them, and how to run and report them. BMC Med 2018;16:29. 10.1186/s12916-018-1017-7
    1. Jaki T, Wason JMS. Multi-arm multi-stage trials can improve the efficiency of finding effective treatments for stroke: a case study. BMC Cardiovasc Disord 2018;18:215. 10.1186/s12872-018-0956-4
    1. Parmar MK, Sydes MR, Cafferty FH, et al. Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols. In: Clinical Trials. SAGE Publications Sage UK, 2017: 451-61, 10.1177/1740774517725697.
    1. Porcher R, Lecocq B, Vray M, participants of Round Table N° 2 de Giens XXVI Adaptive methods: when and how should they be used in clinical trials? Therapie 2011;66:319-26, 309-17. 10.2515/therapie/2011044
    1. Dimairo M, Boote J, Julious SA, Nicholl JP, Todd S. Missing steps in a staircase: a qualitative study of the perspectives of key stakeholders on the use of adaptive designs in confirmatory trials. Trials 2015;16:430. 10.1186/s13063-015-0958-9
    1. Dimairo M, Julious SA, Todd S, Nicholl JP, Boote J. Cross-sector surveys assessing perceptions of key stakeholders towards barriers, concerns and facilitators to the appropriate use of adaptive designs in confirmatory trials. Trials 2015;16:585. 10.1186/s13063-015-1119-x
    1. Meurer WJ, Legocki L, Mawocha S, et al. Attitudes and opinions regarding confirmatory adaptive clinical trials: a mixed methods analysis from the Adaptive Designs Accelerating Promising Trials into Treatments (ADAPT-IT) project. Trials 2016;17:373. 10.1186/s13063-016-1493-z
    1. Morgan CC, Huyck S, Jenkins M, et al. Adaptive design: results of 2012 survey on perception and use. Ther Innov Regul Sci 2014;48:473-81. 10.1177/2168479014522468
    1. Coffey CS, Levin B, Clark C, et al. Overview, hurdles, and future work in adaptive designs: perspectives from a National Institutes of Health-funded workshop. Clin Trials 2012;9:671-80. 10.1177/1740774512461859
    1. Quinlan J, Gaydos B, Maca J, Krams M. Barriers and opportunities for implementation of adaptive designs in pharmaceutical product development. Clin Trials 2010;7:167-73. 10.1177/1740774510361542
    1. Coffey CS, Kairalla JA. Adaptive clinical trials: progress and challenges. Drugs R D 2008;9:229-42. 10.2165/00126839-200809040-00003
    1. Hartford A, Thomann M, Chen X, et al. Adaptive designs: results of 2016 survey on perception and use. Ther Innov Regul Sci 2018:2168479018807715. 10.1177/2168479018807715
    1. Phillips AJ, Keene ON, PSI Adaptive Design Expert Group Adaptive designs for pivotal trials: discussion points from the PSI Adaptive Design Expert Group. Pharm Stat 2006;5:61-6. 10.1002/pst.206
    1. Rong Y. Regulations on adaptive design clinical trials. Pharm Regul Aff 2014;3 10.4172/2167-7689.1000116
    1. Bauer P, Brannath W. The advantages and disadvantages of adaptive designs for clinical trials. Drug Discov Today 2004;9:351-7. 10.1016/S1359-6446(04)03023-5
    1. Huskins WC, Fowler VG, Jr, Evans S. Adaptive designs for clinical trials: application to healthcare epidemiology research. Clin Infect Dis 2018;66:1140-6. 10.1093/cid/cix907.
    1. Chaitman BR, Pepine CJ, Parker JO, et al. Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004;291:309-16. 10.1001/jama.291.3.309
    1. Zajicek JP, Hobart JC, Slade A, Barnes D, Mattison PG, MUSEC Research Group Multiple sclerosis and extract of cannabis: results of the MUSEC trial. J Neurol Neurosurg Psychiatry 2012;83:1125-32. 10.1136/jnnp-2012-302468
    1. Miller E, Gallo P, He W, et al. DIA’s Adaptive Design Scientific Working Group (ADSWG): best practices case studies for “less well-understood” adaptive designs. Ther Innov Regul Sci 2017;51:77-88. 10.1177/2168479016665434
    1. Wang S-J, Peng H, Hung HJ. Evaluation of the extent of adaptation to sample size in clinical trials for cardiovascular and CNS diseases. Contemp Clin Trials 2018;67:31-6. 10.1016/j.cct.2018.02.004
    1. Chen YH, Li C, Lan KK. Sample size adjustment based on promising interim results and its application in confirmatory clinical trials. Clin Trials 2015;12:584-95. 10.1177/1740774515594378
    1. Jennison C, Turnbull BW. Adaptive sample size modification in clinical trials: start small then ask for more? Stat Med 2015;34:3793-810. 10.1002/sim.6575
    1. Mehta CR, Pocock SJ. Adaptive increase in sample size when interim results are promising: a practical guide with examples. Stat Med 2011;30:3267-84. 10.1002/sim.4102
    1. Chuang-Stein C, Anderson K, Gallo P, et al. Sample size reestimation: a review and recommendations. Drug Inf J 2006;40:475-84. 10.1177/216847900604000413
    1. Friede T, Kieser M. A comparison of methods for adaptive sample size adjustment. Stat Med 2001;20:3861-73. 10.1002/sim.972
    1. Friede T, Kieser M. Sample size recalculation for binary data in internal pilot study designs. Pharm Stat 2004;3:269-79. 10.1002/pst.140
    1. Friede T, Kieser M. Sample size recalculation in internal pilot study designs: a review. Biom J 2006;48:537-55. 10.1002/bimj.200510238
    1. Stevely A, Dimairo M, Todd S, et al. An investigation of the shortcomings of the CONSORT 2010 statement for the reporting of group sequential randomised controlled trials: a methodological systematic review. PLoS One 2015;10:e0141104. 10.1371/journal.pone.0141104
    1. Pritchett Y, Jemiai Y, Chang Y, et al. The use of group sequential, information-based sample size re-estimation in the design of the PRIMO study of chronic kidney disease. Clin Trials 2011;8:165-74. 10.1177/1740774511399128
    1. Jennison C, Turnbull BW. Group Sequential Methods with Applications to Clinical Trials. Chapman & Hall/CRC, 2000.
    1. Whitehead J. The Design and Analysis of Sequential Clinical Trials. Revised 2nd ed. John Wiley & Sons, 2000.
    1. Mehta CR, Tsiatis AA. Flexible sample size considerations using information-based interim monitoring. Drug Inf J 2001;35:1095-112. 10.1177/009286150103500407
    1. Herson J, Buyse M, Wittes JT. On stopping a randomized clinical trial for futility. In: Kowalski J, Piantadosi S, eds. Designs for Clinical Trials: Perspectives on Current Issues. Springer, 2012: 109-37 10.1007/978-1-4614-0140-7_5
    1. Gallo P, Mao L, Shih VH. Alternative views on setting clinical trial futility criteria. J Biopharm Stat 2014;24:976-93. 10.1080/10543406.2014.932285
    1. Lachin JM. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit. Clin Trials 2009;6:565-73. 10.1177/1740774509350327
    1. Pushpakom SP, Taylor C, Kolamunnage-Dona R, et al. Telmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral therapy. BMJ Open 2015;5:e009566. 10.1136/bmjopen-2015-009566
    1. Sydes MR, Parmar MKB, Mason MD, et al. Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials 2012;13:168. 10.1186/1745-6215-13-168
    1. Parmar MKB, Barthel FM-S, Sydes M, et al. Speeding up the evaluation of new agents in cancer. J Natl Cancer Inst 2008;100:1204-14. 10.1093/jnci/djn267
    1. Cohen DR, Todd S, Gregory WM, Brown JM. Adding a treatment arm to an ongoing clinical trial: a review of methodology and practice. Trials 2015;16:179. 10.1186/s13063-015-0697-y
    1. Magirr D, Stallard N, Jaki T. Flexible sequential designs for multi-arm clinical trials. Stat Med 2014;33:3269-79. 10.1002/sim.6183
    1. Hommel G. Adaptive modifications of hypotheses after an interim analysis. Biometrical J 2001;43:581-9. 10.1002/1521-4036(200109)43:5<581::AID-BIMJ581>;2-J
    1. Jaki T. Multi-arm clinical trials with treatment selection: what can be gained and at what price? Clin Investig (Lond) 2015;5:393-9 10.4155/cli.15.13.
    1. Wason J, Magirr D, Law M, Jaki T. Some recommendations for multi-arm multi-stage trials. Stat Methods Med Res 2016;25:716-27. 10.1177/0962280212465498
    1. Wason J, Stallard N, Bowden J, Jennison C. A multi-stage drop-the-losers design for multi-arm clinical trials. Stat Methods Med Res 2017;26:508-24. 10.1177/0962280214550759
    1. Ghosh P, Liu L, Senchaudhuri P, Gao P, Mehta C. Design and monitoring of multi-arm multi-stage clinical trials. Biometrics 2017;73:1289-99. 10.1111/biom.12687
    1. Heritier S, Lô SN, Morgan CC. An adaptive confirmatory trial with interim treatment selection: practical experiences and unbalanced randomization. Stat Med 2011;30:1541-54. 10.1002/sim.4179
    1. Posch M, Koenig F, Branson M, Brannath W, Dunger-Baldauf C, Bauer P. Testing and estimation in flexible group sequential designs with adaptive treatment selection. Stat Med 2005;24:3697-714. 10.1002/sim.2389
    1. Bauer P, Kieser M. Combining different phases in the development of medical treatments within a single trial. Stat Med 1999;18:1833-48. 10.1002/(SICI)1097-0258(19990730)18:14<1833::AID-SIM221>;2-3
    1. Bretz F, Koenig F, Brannath W, Glimm E, Posch M. Adaptive designs for confirmatory clinical trials. Stat Med 2009;28:1181-217. 10.1002/sim.3538
    1. Giles FJ, Kantarjian HM, Cortes JE, et al. Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. J Clin Oncol 2003;21:1722-7. 10.1200/JCO.2003.11.016
    1. Grieve AP. Response-adaptive clinical trials: case studies in the medical literature. Pharm Stat 2017;16:64-86. 10.1002/pst.1778
    1. Hu F, Rosenberger WF. The theory of response-adaptive randomization in clinical trials. John Wiley & Sons, 2006. 10.1002/047005588X
    1. Nowacki AS, Zhao W, Palesch YY. A surrogate-primary replacement algorithm for response-adaptive randomization in stroke clinical trials. Stat Methods Med Res 2017;26:1078-92. 10.1177/0962280214567142.
    1. Eickhoff JC, Kim K, Beach J, Kolesar JM, Gee JR. A Bayesian adaptive design with biomarkers for targeted therapies. Clin Trials 2010;7:546-56. 10.1177/1740774510372657
    1. Williamson SF, Jacko P, Villar SS, Jaki T. A Bayesian adaptive design for clinical trials in rare diseases. Comput Stat Data Anal 2017;113:136-53. 10.1016/j.csda.2016.09.006
    1. Berry DA, Eick SG. Adaptive assignment versus balanced randomization in clinical trials: a decision analysis. Stat Med 1995;14:231-46. 10.1002/sim.4780140302
    1. Chen YH, Gesser R, Luxembourg A. A seamless phase IIB/III adaptive outcome trial: design rationale and implementation challenges. Clin Trials 2015;12:84-90. 10.1177/1740774514552110.
    1. Cuffe RL, Lawrence D, Stone A, Vandemeulebroecke M. When is a seamless study desirable? Case studies from different pharmaceutical sponsors. Pharm Stat 2014;13:229-37. 10.1002/pst.1622
    1. Donohue JF, Fogarty C, Lötvall J, et al. INHANCE Study Investigators Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010;182:155-62. 10.1164/rccm.200910-1500OC
    1. Bretz F, Schmidli H, König F, Racine A, Maurer W. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts. Biom J 2006;48:623-34. 10.1002/bimj.200510232
    1. Bauer P, Bretz F, Dragalin V, König F, Wassmer G. Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls. Stat Med 2016;35:325-47. 10.1002/sim.6472
    1. Koenig F, Brannath W, Bretz F, Posch M. Adaptive Dunnett tests for treatment selection. Stat Med 2008;27:1612-25. 10.1002/sim.3048
    1. Antoniou M, Jorgensen AL, Kolamunnage-Dona R. Biomarker-guided adaptive trial designs in phase II and phase III: a methodological review. PLoS One 2016;11:e0149803. 10.1371/journal.pone.0149803
    1. Liu S, Lee JJ. An overview of the design and conduct of the BATTLE trials. Chin Clin Oncol 2015;4:33. 10.3978/j.issn.2304-3865.2015.06.07.
    1. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009;86:97-100. 10.1038/clpt.2009.68
    1. Renfro LA, Mallick H, An MW, Sargent DJ, Mandrekar SJ. Clinical trial designs incorporating predictive biomarkers. Cancer Treat Rev 2016;43:74-82. 10.1016/j.ctrv.2015.12.008
    1. Ondra T, Dmitrienko A, Friede T, et al. Methods for identification and confirmation of targeted subgroups in clinical trials: A systematic review. J Biopharm Stat 2016;26:99-119. 10.1080/10543406.2015.1092034
    1. Chiu Y-D, Koenig F, Posch M, Jaki T. Design and estimation in clinical trials with subpopulation selection. Stat Med 2018;37:4335-52. 10.1002/sim.7925
    1. Graf AC, Wassmer G, Friede T, Gera RG, Posch M. Robustness of testing procedures for confirmatory subpopulation analyses based on a continuous biomarker. Stat Methods Med Res 2019;28:1879-92. 10.1177/0962280218777538.
    1. Joshi A, Zhang J, Fang L. Statistical design for a confirmatory trial with a continuous predictive biomarker: A case study. Contemp Clin Trials 2017;63:19-29. 10.1016/j.cct.2017.05.010
    1. Wang SJ, Hung HMJ. Adaptive enrichment with subpopulation selection at interim: methodologies, applications and design considerations. Contemp Clin Trials 2013;36:673-81. 10.1016/j.cct.2013.09.008
    1. Hünseler C, Balling G, Röhlig C, et al. Clonidine Study Group Continuous infusion of clonidine in ventilated newborns and infants: a randomized controlled trial. Pediatr Crit Care Med 2014;15:511-22. 10.1097/PCC.0000000000000151
    1. Hommel G, Kropf S. Clinical trials with an adaptive choice of hypotheses. Drug Inf J 2001;35:1423-9. 10.1177/009286150103500438
    1. Branson M, Whitehead J. Estimating a treatment effect in survival studies in which patients switch treatment. Stat Med 2002;21:2449-63. 10.1002/sim.1219
    1. Shao J, Chang M, Chow S-C. Statistical inference for cancer trials with treatment switching. Stat Med 2005;24:1783-90. 10.1002/sim.2128
    1. Skrivanek Z, Gaydos BL, Chien JY, et al. Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5). Diabetes Obes Metab 2014;16:748-56. 10.1111/dom.12305
    1. Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med 2015;372:735-46. 10.1056/NEJMoa1404710
    1. Mehta CR, Liu L, Theuer C. An adaptive population enrichment phase III trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS trial). Ann Oncol 2019;30:103-8. 10.1093/annonc/mdy464
    1. Nogueira RG, Jadhav AP, Haussen DC, et al. DAWN Trial Investigators Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med 2018;378:11-21. 10.1056/NEJMoa1706442
    1. Collignon O, Koenig F, Koch A, et al. Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency. Trials 2018;19:642. 10.1186/s13063-018-3012-x
    1. Lewis RJ, Angus DC, Laterre PF, et al. Selepressin Evaluation Programme for Sepsis-induced Shock-Adaptive Clinical Trial Rationale and design of an adaptive phase 2b/3 clinical trial of selepressin for adults in septic shock: Selepressin evaluation programme for sepsis-induced shock - Adaptive clinical trial. Ann Am Thorac Soc 2018;15:250-7. 10.1513/AnnalsATS.201708-669SD
    1. Cui L, Hung HM, Wang SJ. Modification of sample size in group sequential clinical trials. Biometrics 1999;55:853-7. 10.1111/j.0006-341X.1999.00853.x
    1. Jenkins M, Stone A, Jennison C. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints. Pharm Stat 2011;10:347-56. 10.1002/pst.472
    1. Wason JMS, Abraham JE, Baird RD, et al. A Bayesian adaptive design for biomarker trials with linked treatments. Br J Cancer 2015;113:699-705. 10.1038/bjc.2015.278
    1. Saville BR, Berry SM. Efficiencies of platform clinical trials: A vision of the future. Clin Trials 2016;13:358-66. 10.1177/1740774515626362
    1. Bauer P, Einfalt J. Application of adaptive designs--a review. Biom J 2006;48:493-506. 10.1002/bimj.200510204
    1. Elsäßer A, Regnstrom J, Vetter T, et al. Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency. Trials 2014;15:383. 10.1186/1745-6215-15-383
    1. Food and Drug Administration. Guidance for industry: adaptive design clinical trials for drugs and biologics. 2010. .
    1. CHMP. Reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design. 2007. .
    1. Food and Drug Administration. Adaptive designs for clinical trials of drugs and biologics: guidance for industry. 2019. .
    1. Yang X, Thompson L, Chu J, et al. Adaptive design practice at the Center for Devices and Radiological Health (CDRH), January 2007 to May 2013. Ther Innov Regul Sci 2016;50:710-7. 10.1177/2168479016656027
    1. Mistry P, Dunn JA, Marshall A. A literature review of applied adaptive design methodology within the field of oncology in randomised controlled trials and a proposed extension to the CONSORT guidelines. BMC Med Res Methodol 2017;17:108. 10.1186/s12874-017-0393-6
    1. Hatfield I, Allison A, Flight L, Julious SA, Dimairo M. Adaptive designs undertaken in clinical research: a review of registered clinical trials. Trials 2016;17:150. 10.1186/s13063-016-1273-9
    1. Sato A, Shimura M, Gosho M. Practical characteristics of adaptive design in phase 2 and 3 clinical trials. J Clin Pharm Ther 2018;43:170-80. 10.1111/jcpt.12617.
    1. Bothwell LE, Avorn J, Khan NF, Kesselheim AS. Adaptive design clinical trials: a review of the literature and . BMJ Open 2018;8:e018320. 10.1136/bmjopen-2017-018320
    1. Gosho M, Sato Y, Nagashima K, Takahashi S. Trends in study design and the statistical methods employed in a leading general medicine journal. J Clin Pharm Ther 2018;43:36-44. 10.1111/jcpt.12605
    1. Cerqueira FP, Jesus AMC, Cotrim MD. Adaptive design: a review of the technical, statistical, and regulatory aspects of implementation in a clinical trial. Ther Innov Regul Sci 2019:2168479019831240. 10.1177/2168479019831240
    1. Lin M, Lee S, Zhen B, et al. CBER’s experience with adaptive design clinical trials. Ther Innov Regul Sci 2016;50:195-203. 10.1177/2168479015604181
    1. Dimairo M. The Utility of Adaptive Designs in Publicly Funded Confirmatory Trials 2016. .
    1. Detry MA, Lewis RJ, Broglio KR, et al. Standards for the design, conduct, and evaluation of adaptive randomized clinical trials. 2012.
    1. Campbell G. Similarities and differences of Bayesian designs and adaptive designs for medical devices: a regulatory view. Stat Biopharm Res 2013;5:356-68. 10.1080/19466315.2013.846873
    1. Gaydos B, Anderson KM, Berry D, et al. Good practices for adaptive clinical trials in pharmaceutical product development. Ther Innov Regul Sci 2009;43:539-56. 10.1177/009286150904300503.
    1. Chow S-C, Chang M, Pong A. Statistical consideration of adaptive methods in clinical development. J Biopharm Stat 2005;15:575-91. 10.1081/BIP-200062277
    1. Chow S-C, Corey R. Benefits, challenges and obstacles of adaptive clinical trial designs. Orphanet J Rare Dis 2011;6:79. 10.1186/1750-1172-6-79
    1. Quinlan J, Krams M. Implementing adaptive designs: logistical and operational considerations. Drug Inf J 2006;40:437-44. 10.1177/216847900604000409
    1. Wang SJ. Perspectives on the use of adaptive designs in clinical trials. Part I. Statistical considerations and issues. J Biopharm Stat 2010;20:1090-7. 10.1080/10543406.2010.514446
    1. Dimairo M, Todd S, Julious S, et al. ACE Project Protocol Version 2.3: Development of a CONSORT Extension for adaptive clinical trials. EQUATOR Netw. 2016. .
    1. Moher D, Schulz KF, Simera I, Altman DG. Guidance for developers of health research reporting guidelines. PLoS Med 2010;7:e1000217. 10.1371/journal.pmed.1000217
    1. Rosenberg MJ. The agile approach to adaptive research: optimizing efficiency in clinical development. 1st ed John Wiley & Sons, Inc, 2010. 10.1002/9780470599686
    1. Avery KNL, Williamson PR, Gamble C, et al. members of the Internal Pilot Trials Workshop supported by the Hubs for Trials Methodology Research Informing efficient randomised controlled trials: exploration of challenges in developing progression criteria for internal pilot studies. BMJ Open 2017;7:e013537. 10.1136/bmjopen-2016-013537
    1. Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of multi-arm parallel-group randomized trials: extension of the CONSORT 2010 statement. JAMA 2019;321:1610-20. 10.1001/jama.2019.3087
    1. Campbell MK, Piaggio G, Elbourne DR, Altman DG, CONSORT Group Consort 2010 statement: extension to cluster randomised trials. BMJ 2012;345:e5661. 10.1136/bmj.e5661
    1. Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ 2019;366:l4378. 10.1136/bmj.l4378
    1. Piaggio G, Elbourne DR, Pocock SJ, Evans SJ, Altman DG, CONSORT Group Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA 2012;308:2594-604. 10.1001/jama.2012.87802
    1. Hopewell S, Clarke M, Moher D, et al. CONSORT Group CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med 2008;5:e20. 10.1371/journal.pmed.0050020
    1. Hopewell S, Clarke M, Moher D, et al. CONSORT Group CONSORT for reporting randomised trials in journal and conference abstracts. Lancet 2008;371:281-3. 10.1016/S0140-6736(07)61835-2
    1. Ioannidis JPA, Evans SJW, Gøtzsche PC, et al. CONSORT Group Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 2004;141:781-8. 10.7326/0003-4819-141-10-200411160-00009
    1. MEDLINE. Adaptive Clinical Trial MeSH Descriptor Data 2019. 2019. .
    1. Backonja M, Williams L, Miao X, Katz N, Chen C. Safety and efficacy of neublastin in painful lumbosacral radiculopathy: a randomized, double-blinded, placebo-controlled phase 2 trial using Bayesian adaptive design (the SPRINT trial). Pain 2017;158:1802-12. 10.1097/j.pain.0000000000000983
    1. Barnes PJ, Pocock SJ, Magnussen H, et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulm Pharmacol Ther 2010;23:165-71. 10.1016/j.pupt.2010.01.003
    1. Jones AE, Puskarich MA, Shapiro NI, et al. Effect of levocarnitine vs placebo as an adjunctive treatment for septic shock: The Rapid Administration of Carnitine in Sepsis (RACE) Randomized Clinical Trial. JAMA Netw Open 2018;1:e186076. 10.1001/jamanetworkopen.2018.6076
    1. Khalil EAG, Weldegebreal T, Younis BM, et al. Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trial. PLoS Negl Trop Dis 2014;8:e2613. 10.1371/journal.pntd.0002613
    1. Steg PG, Mehta SR, Pollack CV, Jr, et al. TAO Investigators Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial. JAMA 2013;310:1145-55. 10.1001/jama.2013.277165
    1. McMurray JJV, Packer M, Desai AS, et al. PARADIGM-HF Investigators and Committees Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004. 10.1056/NEJMoa1409077
    1. Rosenblum M, Hanley DF. Adaptive enrichment designs for stroke clinical trials. Stroke 2017;48:2021-5. 10.1161/STROKEAHA.116.015342
    1. Lachin JM. A review of methods for futility stopping based on conditional power. Stat Med 2005;24:2747-64. 10.1002/sim.2151
    1. Proschan M, Lan KKG, Wittes JT. Power: conditional, unconditional, and predictive. In: Statistical Monitoring of Clinical Trials - A Unified Approach. Springer, 2006: 43-66.
    1. Lan KG, Simon R, Halperin M. Stochastically curtailed tests in long–term clinical trials. Seq Anal 1982;37-41. .
    1. Bauer P, Koenig F. The reassessment of trial perspectives from interim data--a critical view. Stat Med 2006;25:23-36. 10.1002/sim.2180
    1. Herson J. Predictive probability early termination plans for phase II clinical trials. Biometrics 1979;35:775-83. 10.2307/2530109
    1. Choi SC, Pepple PA. Monitoring clinical trials based on predictive probability of significance. Biometrics 1989;45:317-23. 10.2307/2532056
    1. Spiegelhalter DJ, Freedman LS, Blackburn PR. Monitoring clinical trials: conditional or predictive power? Control Clin Trials 1986;7:8-17. 10.1016/0197-2456(86)90003-6
    1. Skrivanek Z, Berry S, Berry D, et al. Application of adaptive design methodology in development of a long-acting glucagon-like peptide-1 analog (dulaglutide): statistical design and simulations. J Diabetes Sci Technol 2012;6:1305-18. 10.1177/193229681200600609
    1. Ouellet D. Benefit-risk assessment: the use of clinical utility index. Expert Opin Drug Saf 2010;9:289-300. 10.1517/14740330903499265
    1. Thadhani R, Appelbaum E, Chang Y, et al. Vitamin D receptor activation and left ventricular hypertrophy in advanced kidney disease. Am J Nephrol 2011;33:139-49. 10.1159/000323551
    1. Thadhani R, Appelbaum E, Pritchett Y, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 2012;307:674-84. 10.1001/jama.2012.120
    1. Gould AL, Shih WJ. Sample size re-estimation without unblinding for normally distributed outcomes with unknown variance. Commun Stat Theory Methods 1992;21:2833-53. 10.1080/03610929208830947
    1. Gould AL. Planning and revising the sample size for a trial. Stat Med 1995;14:1039-51, discussion 1053-5. 10.1002/sim.4780140922
    1. Kieser M, Friede T. Blinded sample size reestimation in multiarmed clinical trials. Drug Inf J 2000;34:455-60. 10.1177/009286150003400214
    1. Posch M, Proschan MA. Unplanned adaptations before breaking the blind. Stat Med 2012;31:4146-53. 10.1002/sim.5361
    1. Chataway J, Nicholas R, Todd S, et al. A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis. Mult Scler 2011;17:81-8. 10.1177/1352458510382129
    1. Fleming TR, Powers JH. Biomarkers and surrogate endpoints in clinical trials. Stat Med 2012;31:2973-84. 10.1002/sim.5403
    1. Heatley G, Sood P, Goldstein D, et al. MOMENTUM 3 Investigators Clinical trial design and rationale of the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 (MOMENTUM 3) investigational device exemption clinical study protocol. J Heart Lung Transplant 2016;35:528-36. 10.1016/j.healun.2016.01.021
    1. Barrington P, Chien JY, Showalter HDH, et al. A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes. Diabetes Obes Metab 2011;13:426-33. 10.1111/j.1463-1326.2011.01364.x
    1. Geiger MJ, Skrivanek Z, Gaydos B, Chien J, Berry S, Berry D. An adaptive, dose-finding, seamless phase 2/3 study of a long-acting glucagon-like peptide-1 analog (dulaglutide): trial design and baseline characteristics. J Diabetes Sci Technol 2012;6:1319-27. 10.1177/193229681200600610
    1. James ND, Sydes MR, Mason MD, et al. STAMPEDE investigators Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. Lancet Oncol 2012;13:549-58. 10.1016/S1470-2045(12)70088-8
    1. Dwan K, Kirkham JJ, Williamson PR, Gamble C. Selective reporting of outcomes in randomised controlled trials in systematic reviews of cystic fibrosis. BMJ Open 2013;3:e002709. 10.1136/bmjopen-2013-002709
    1. Dwan K, Altman DG, Arnaiz JA, et al. Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS One 2008;3:e3081. 10.1371/journal.pone.0003081
    1. Lancee M, Lemmens CMC, Kahn RS, Vinkers CH, Luykx JJ. Outcome reporting bias in randomized-controlled trials investigating antipsychotic drugs. Transl Psychiatry 2017;7:e1232. 10.1038/tp.2017.203
    1. Evans S. When and how can endpoints be changed after initiation of a randomized clinical trial? PLoS Clin Trials 2007;2:e18. 10.1371/journal.pctr.0020018
    1. Wason JMS, Mander AP, Thompson SG. Optimal multistage designs for randomised clinical trials with continuous outcomes. Stat Med 2012;31:301-12. 10.1002/sim.4421
    1. Wason JMS, Mander AP. Minimizing the maximum expected sample size in two-stage Phase II clinical trials with continuous outcomes. J Biopharm Stat 2012;22:836-52. 10.1080/10543406.2010.528104
    1. Cook JA, Julious SA, Sones W, et al. DELTA2 guidance on choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial. BMJ 2018;363:k3750. 10.1136/bmj.k3750
    1. Bell ML. New guidance to improve sample size calculations for trials: eliciting the target difference. Trials 2018;19:605. 10.1186/s13063-018-2894-y
    1. Dunnett C. Selection of the best treatment in comparison to a control with an application to a medical trial. In: Santer T, Tamhane A, eds. Design of experiments : ranking and selection. Marcel Dekker, 1984: 47-66, .
    1. Magirr D, Jaki T, Whitehead J. A generalized Dunnett test for multi-arm multi-stage clinical studies with treatment selection. Biometrika 2012;99:494-501. 10.1093/biomet/ass002
    1. Whitehead J, Jaki T. One- and two-stage design proposals for a phase II trial comparing three active treatments with control using an ordered categorical endpoint. Stat Med 2009;28:828-47. 10.1002/sim.3508
    1. Jaki T, Magirr D. Designing multi-arm multi-stage studies: R Package ‘MAMS’. 2014.
    1. Hwang IK, Shih WJ, De Cani JS. Group sequential designs using a family of type I error probability spending functions. Stat Med 1990;9:1439-45. 10.1002/sim.4780091207
    1. Steg PG, Mehta SR, Pollack CV, Jr, et al. Design and rationale of the treatment of acute coronary syndromes with otamixaban trial: a double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non-ST-segment elevation acute coronary syndromes with a planned early invasive strategy. Am Heart J 2012;164:817-24.e13. 10.1016/j.ahj.2012.10.001
    1. Lorch U, O’Kane M, Taubel J. Three steps to writing adaptive study protocols in the early phase clinical development of new medicines. BMC Med Res Methodol 2014;14:84. 10.1186/1471-2288-14-84
    1. Guetterman TC, Fetters MD, Legocki LJ, et al. Reflections on the Adaptive Designs Accelerating Promising Trials Into Treatments (ADAPT-IT) Process-findings from a qualitative study. Clin Res Regul Aff 2015;32:121-30. 10.3109/10601333.2015.1079217
    1. Pocock SJ. Group sequential methods in the design and analysis of clinical trials. Biometrika 1977;64:191 10.1093/biomet/64.2.191
    1. O’Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979;35:549-56. 10.2307/2530245
    1. Gsponer T, Gerber F, Bornkamp B, Ohlssen D, Vandemeulebroecke M, Schmidli H. A practical guide to Bayesian group sequential designs. Pharm Stat 2014;13:71-80. 10.1002/pst.1593
    1. Emerson SS, Kittelson JM, Gillen DL. Frequentist evaluation of group sequential clinical trial designs. Stat Med 2007;26:5047-80. 10.1002/sim.2901
    1. Togo K, Iwasaki M. Optimal timing for interim analyses in clinical trials. J Biopharm Stat 2013;23:1067-80. 10.1080/10543406.2013.813522
    1. Xi D, Gallo P, Ohlssen D. On the optimal timing of futility interim analyses. Stat Biopharm Res 2017;9:293-301. 10.1080/19466315.2017.1340906
    1. Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998;339:1979-84. 10.1056/NEJM199812313392704
    1. Medical Research Council Oesophageal Cancer Working Group Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002;359:1727-33. 10.1016/S0140-6736(02)08651-8
    1. Bauer P, Köhne K. Evaluation of experiments with adaptive interim analyses. Biometrics 1994;50:1029-41. 10.2307/2533441
    1. Stahl M, Walz MK, Riera-Knorrenschild J, et al. Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): Long-term results of a controlled randomised trial. Eur J Cancer 2017;81:183-90. 10.1016/j.ejca.2017.04.027
    1. Pocock SJ, Clayton TC, Stone GW. Challenging issues in clinical trial design: part 4 of a 4-part series on statistics for clinical trials. J Am Coll Cardiol 2015;66:2886-98. 10.1016/j.jacc.2015.10.051
    1. Jansen JO, Pallmann P, MacLennan G, Campbell MK, UK-REBOA Trial Investigators Bayesian clinical trial designs: Another option for trauma trials? J Trauma Acute Care Surg 2017;83:736-41. 10.1097/TA.0000000000001638
    1. Jiang Y, Zhao W, Durkalski-Mauldin V. Impact of adaptation algorithm, timing, and stopping boundaries on the performance of Bayesian response adaptive randomization in confirmative trials with a binary endpoint. Contemp Clin Trials 2017;62:114-20. 10.1016/j.cct.2017.08.019
    1. Du Y, Wang X, Jack Lee J. Simulation study for evaluating the performance of response-adaptive randomization. Contemp Clin Trials 2015;40:15-25. 10.1016/j.cct.2014.11.006
    1. Chappell R, Durkalski V, Joffe S. University of Pennsylvania ninth annual conference on statistical issues in clinical trials: Where are we with adaptive clinical trial designs? (morning panel discussion). Clin Trials 2017;14:441-50. 10.1177/1740774517723590
    1. Brown CH, Ten Have TR, Jo B, et al. Adaptive designs for randomized trials in public health. Annu Rev Public Health 2009;30:1-25. 10.1146/annurev.publhealth.031308.100223
    1. Fleming TR, Sharples K, McCall J, Moore A, Rodgers A, Stewart R. Maintaining confidentiality of interim data to enhance trial integrity and credibility. Clin Trials 2008;5:157-67. 10.1177/1740774508089459
    1. He W, Gallo P, Miller E, et al. Addressing challenges and opportunities of “less well-understood” adaptive designs. Ther Innov Regul Sci 2017;51:60-8. 10.1177/2168479016663265
    1. Husten L. Orexigen released interim data without approval of trial leaders. Forbes. 2015. .
    1. Gallo P. Confidentiality and trial integrity issues for adaptive designs. Drug Inf J 2006;40:445-50. 10.1177/216847900604000410
    1. Chow S-C, Corey R, Lin M. On the independence of data monitoring committee in adaptive design clinical trials. J Biopharm Stat 2012;22:853-67. 10.1080/10543406.2012.676536
    1. Herson J. Coordinating data monitoring committees and adaptive clinical trial designs. Drug Inf J 2008;42:297-301. 10.1177/009286150804200401
    1. Akacha M, Bretz F, Ohlssen D, et al. Estimands and their role in clinical trials. Stat Biopharm Res 2017;9:268-71. 10.1080/19466315.2017.1302358
    1. Akacha M, Bretz F, Ruberg S. Estimands in clinical trials - broadening the perspective. Stat Med 2017;36:5-19. 10.1002/sim.7033. 10.1002/sim.7033
    1. Gu X, Chen N, Wei C, et al. Bayesian two-stage biomarker-based adaptive design for targeted therapy development. Stat Biosci 2016;8:99-128. 10.1007/s12561-014-9124-2
    1. Wittes J. Stopping a trial early - and then what? Clin Trials 2012;9:714-20. 10.1177/1740774512454600
    1. Bassler D, Briel M, Montori VM, et al. STOPIT-2 Study Group Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA 2010;303:1180-7. 10.1001/jama.2010.310
    1. Wears RL. Are we there yet? Early stopping in clinical trials. Ann Emerg Med 2015;65:214-5. 10.1016/j.annemergmed.2014.12.020
    1. Hughes MD, Pocock SJ. Stopping rules and estimation problems in clinical trials. Stat Med 1988;7:1231-42. 10.1002/sim.4780071204
    1. Pocock SJ, Hughes MD. Practical problems in interim analyses, with particular regard to estimation. Control Clin Trials 1989;10(Suppl):209S-21S. 10.1016/0197-2456(89)90059-7
    1. Walter SD, Han H, Briel M, Guyatt GH. Quantifying the bias in the estimated treatment effect in randomized trials having interim analyses and a rule for early stopping for futility. Stat Med 2017;36:1506-18. 10.1002/sim.7242
    1. Wang H, Rosner GL, Goodman SN. Quantifying over-estimation in early stopped clinical trials and the “freezing effect” on subsequent research. Clin Trials 2016;13:621-31. 10.1177/1740774516649595
    1. Freidlin B, Korn EL. Stopping clinical trials early for benefit: impact on estimation. Clin Trials 2009;6:119-25. 10.1177/1740774509102310
    1. Bauer P, Koenig F, Brannath W, Posch M. Selection and bias--two hostile brothers. Stat Med 2010;29:1-13. 10.1002/sim.3716.
    1. Walter SD, Guyatt GH, Bassler D, Briel M, Ramsay T, Han HD. Randomised trials with provision for early stopping for benefit (or harm): The impact on the estimated treatment effect. Stat Med 2019;38:2524-43. 10.1002/sim.8142
    1. Flight L, Arshad F, Barnsley R, et al. A review of clinical trials with an adaptive design and health economic analysis. Value Health 2019;22:391-8. 10.1016/j.jval.2018.11.008
    1. Whitehead J. Supplementary analysis at the conclusion of a sequential clinical trial. Biometrics 1986;42:461-71. 10.2307/2531197
    1. Cameron C, Ewara E, Wilson FR, et al. The Importance of considering differences in study design in network meta-analysis: an application using anti-tumor necrosis factor drugs for ulcerative colitis. Med Decis Making 2017;37:894-904. 10.1177/0272989X17711933
    1. Mehta CR, Bauer P, Posch M, Brannath W. Repeated confidence intervals for adaptive group sequential trials. Stat Med 2007;26:5422-33. 10.1002/sim.3062
    1. Brannath W, König F, Bauer P. Estimation in flexible two stage designs. Stat Med 2006;25:3366-81. 10.1002/sim.2258
    1. Brannath W, Mehta CR, Posch M. Exact confidence bounds following adaptive group sequential tests. Biometrics 2009;65:539-46. 10.1111/j.1541-0420.2008.01101.x
    1. Gao P, Liu L, Mehta C. Exact inference for adaptive group sequential designs. Stat Med 2013;32:3991-4005. 10.1002/sim.5847
    1. Kunzmann K, Benner L, Kieser M. Point estimation in adaptive enrichment designs. Stat Med 2017;36:3935-47. 10.1002/sim.7412
    1. Jennison C, Turnbull BW. Analysis following a sequential test. In: Group Sequential Methods with Applications to Clinical Trials. Chapman & Hall/CRC, 2000: 171-87.
    1. Heritier S, Lloyd CJ, Lô SN. Accurate p-values for adaptive designs with binary endpoints. Stat Med 2017;36:2643-55. 10.1002/sim.7324
    1. Simon R, Simon N. Inference for multimarker adaptive enrichment trials. Stat Med 2017;36:4083-93. 10.1002/sim.7422
    1. Kunz CU, Jaki T, Stallard N. An alternative method to analyse the biomarker-strategy design. Stat Med 2018;37:4636-51. 10.1002/sim.7940
    1. Hack N, Brannath W. Estimation in adaptive group sequential trials. 2011.
    1. Zhu L, Ni L, Yao B. Group sequential methods and software applications. Am Stat 2011;65:127-35. 10.1198/tast.2011.10213
    1. Tymofyeyev Y. A review of available software and capabilities for adaptive designs. In: Practical Considerations for Adaptive Trial Design and Implementation. Springer, 2014: 139-55, 10.1007/978-1-4939-1100-4_8
    1. Hack N, Brannath W, Brueckner M. AGSDest: estimation in adaptive group sequential trials. 2019. .
    1. Fernandes RM, van der Lee JH, Offringa M. A systematic review of the reporting of Data Monitoring Committees’ roles, interim analysis and early termination in pediatric clinical trials. BMC Pediatr 2009;9:77. 10.1186/1471-2431-9-77
    1. Choodari-Oskooei B, Parmar MKB, Royston P, Bowden J. Impact of lack-of-benefit stopping rules on treatment effect estimates of two-arm multi-stage (TAMS) trials with time to event outcome. Trials 2013;14:23. 10.1186/1745-6215-14-23
    1. Bratton DJ. Design issues and extensions of multi-arm multi-stage clinical trials 2015.
    1. Wason JMS, Jaki T. Optimal design of multi-arm multi-stage trials. Stat Med 2012;31:4269-79. 10.1002/sim.5513
    1. Wason J, Stallard N, Bowden J, et al. A multi-stage drop-the-losers design for multi-arm clinical trials. Stat Methods Med Res 2014. 10.1002/sim.6086
    1. Lehmacher W, Wassmer G. Adaptive sample size calculations in group sequential trials. Biometrics 1999;55:1286-90. 10.1111/j.0006-341X.1999.01286.x
    1. Vandemeulebroecke M. An investigation of two-stage tests. Stat Sin 2006;16:933-51.
    1. Graf AC, Bauer P, Glimm E, Koenig F. Maximum type 1 error rate inflation in multiarmed clinical trials with adaptive interim sample size modifications. Biom J 2014;56:614-30. 10.1002/bimj.201300153
    1. Posch M, Bauer P. Adaptive two stage designs and the conditional error function. Biometrical J 1999;41:689-96. 10.1002/(SICI)1521-4036(199910)41:6<689::AID-BIMJ689>;2-P
    1. Proschan MA, Hunsberger SA. Designed extension of studies based on conditional power. Biometrics 1995;51:1315-24. 10.2307/2533262
    1. Brard C, Le Teuff G, Le Deley M-C, et al. Bayesian survival analysis in clinical trials: What methods are used in practice? Clin Trials 2016. 10.1177/1740774516673362.
    1. Wagenmakers E-J, Gronau QF, Stefan A, et al. A Bayesian Perspective on the Proposed FDA Guidelines for Adaptive Clinical Trials. 2018. .
    1. FDA. Guidance, for the use of Bayesian statistics in medical device clinical trials. 2010.
    1. Whitehead J. Overrunning and underrunning in sequential clinical trials. Control Clin Trials 1992;13:106-21. 10.1016/0197-2456(92)90017-T
    1. Hampson LV, Jennison C. Group sequential tests for delayed responses (with discussion). J R Stat Soc Series B Stat Methodol 2013;75:3-54. 10.1111/j.1467-9868.2012.01030.x
    1. Emerson S, Fleming T. Parameter estimation following group sequential hypothesis testing. Biometrika 1990;77:875-92. 10.1093/biomet/77.4.875
    1. Tröger W, Galun D, Reif M, Schumann A, Stanković N, Milićević M. Viscum album [L.] extract therapy in patients with locally advanced or metastatic pancreatic cancer: a randomised clinical trial on overall survival. Eur J Cancer 2013;49:3788-97. 10.1016/j.ejca.2013.06.043
    1. MacArthur RD, Hawkins TN, Brown SJ, et al. Efficacy and safety of crofelemer for noninfectious diarrhea in HIV-seropositive individuals (ADVENT trial): a randomized, double-blind, placebo-controlled, two-stage study. HIV Clin Trials 2013;14:261-73. 10.1310/hct1406-261
    1. Brannath W, Zuber E, Branson M, et al. Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology. Stat Med 2009;28:1445-63. 10.1002/sim.3559
    1. Marcus R, Eric P, Gabriel K. On closed testing procedures with special reference to ordered analysis of variance. Biometrika 1976;63:655-60. 10.1093/biomet/63.3.655
    1. Simes RJ. An improved Bonferroni procedure for multiple tests of significance. Biometrika 1986;73:751 10.1093/biomet/73.3.751.
    1. Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 2011;1:44-53. 10.1158/-10-0010
    1. Pushpakom S, Kolamunnage-Dona R, Taylor C, et al. TAILoR Study Group TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): an adaptive-design, dose-ranging phase IIb randomized trial of telmisartan for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral therapy. Clin Infect Dis 2019;3:ciz589. 10.1093/cid/ciz589
    1. James ND, Sydes MR, Clarke NW, et al. STAMPEDE investigators Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016;387:1163-77. 10.1016/S0140-6736(15)01037-5
    1. Berry SM, Connor JT, Lewis RJ. The platform trial: an efficient strategy for evaluating multiple treatments. JAMA 2015;313:1619-20. 10.1001/jama.2015.2316
    1. Gilson C, Chowdhury S, Parmar MKB, Sydes MR, STAMPEDE Investigators Incorporating Biomarker Stratification into STAMPEDE: an adaptive multi-arm, multi-stage trial platform. Clin Oncol (R Coll Radiol) 2017;29:778-86. 10.1016/j.clon.2017.10.004
    1. Pemberton VL, Evans F, Gulin J, et al. Performance and predictors of recruitment success in National Heart, Lung, and Blood Institute’s cardiovascular clinical trials. Clin Trials 2018;15:444-51. 10.1177/1740774518792271
    1. de Jong MD, Ison MG, Monto AS, et al. Evaluation of intravenous peramivir for treatment of influenza in hospitalized patients. Clin Infect Dis 2014;59:e172-85. 10.1093/cid/ciu632
    1. Harvey LA. Statistical testing for baseline differences between randomised groups is not meaningful. Spinal Cord 2018;56:919. 10.1038/s41393-018-0203-y
    1. Senn S. Testing for baseline balance in clinical trials. Stat Med 1994;13:1715-26. 10.1002/sim.4780131703
    1. de Boer MR, Waterlander WE, Kuijper LDJ, Steenhuis IH, Twisk JW. Testing for baseline differences in randomized controlled trials: an unhealthy research behavior that is hard to eradicate. Int J Behav Nutr Phys Act 2015;12:4. 10.1186/s12966-015-0162-z
    1. Altman DG. Comparability of randomised groups. Stat 1985;34:125 10.2307/2987510.
    1. Koch A. Confirmatory clinical trials with an adaptive design. Biom J 2006;48:574-85. 10.1002/bimj.200510239
    1. Chang M, Chow S-C, Pong A. Adaptive design in clinical research: issues, opportunities, and recommendations. J Biopharm Stat 2006;16:299-309, discussion 311-2. 10.1080/10543400600609718
    1. Gallo P, Chuang-Stein C. What should be the role of homogeneity testing in adaptive trials? Pharm Stat 2009;8:1-4. 10.1002/pst.342
    1. Friede T, Henderson R. Exploring changes in treatment effects across design stages in adaptive trials. Pharm Stat 2009;8:62-72. 10.1002/pst.332
    1. Wang S-J, Brannath W, Brückner M, et al. Unblinded adaptive statistical information design based on clinical endpoint or biomarker. Stat Biopharm Res 2013;5:293-310. 10.1080/19466315.2013.791639
    1. Parker RA. Testing for qualitative interactions between stages in an adaptive study. Stat Med 2010;29:210-8. 10.1002/sim.3757
    1. Gonnermann A, Framke T, Großhennig A, Koch A. No solution yet for combining two independent studies in the presence of heterogeneity. Stat Med 2015;34:2476-80. 10.1002/sim.6473
    1. Gamble C, Krishan A, Stocken D, et al. Guidelines for the content of statistical analysis plans in clinical trials. JAMA 2017;318:2337-43. 10.1001/jama.2017.18556
    1. DeMets DL, Cook TD, Buhr KA. Guidelines for statistical analysis plans. JAMA 2017;318:2301-3. 10.1001/jama.2017.18954
    1. ICH. ICH E9: Statistical principles for clinical trials. 1998.
    1. Thorlund K, Haggstrom J, Park JJ, Mills EJ. Key design considerations for adaptive clinical trials: a primer for clinicians. BMJ 2018;360:k698. 10.1136/bmj.k698

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir